A Phase 1b, Open-label, Dose-finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Axitinib (AG-013736) In Patients With Previously Untreated Advanced Renal Cell Cancer

Trial Profile

A Phase 1b, Open-label, Dose-finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Axitinib (AG-013736) In Patients With Previously Untreated Advanced Renal Cell Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs Avelumab (Primary) ; Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms JAVELIN Renal 100
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Dec 2017 Planned End Date changed from 23 Feb 2019 to 1 Jan 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results (data cut of: Dec 30, 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top